Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.53 | -0.09 | 0.21 | -0.02 |
| FCF Yield | 4.86% | 3.73% | 10.64% | 2.73% |
| EV / EBITDA | 46.44 | 12.09 | 14.40 | 21.58 |
| Quality | ||||
| ROIC | 4.00% | 1.31% | -0.06% | 7.75% |
| Gross Margin | 93.37% | 73.31% | 73.08% | 77.56% |
| Cash Conversion Ratio | -24.07 | 0.95 | -4.13 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.21% | -18.38% | 6.26% | 26.16% |
| Free Cash Flow Growth | 106.76% | -61.60% | 71.23% | 39.72% |
| Safety | ||||
| Net Debt / EBITDA | -1.60 | -0.17 | 0.53 | 2.29 |
| Interest Coverage | -7.44 | 18.20 | 1.69 | 5.29 |
| Efficiency | ||||
| Inventory Turnover | 0.78 | 1.46 | 3.97 | 2.28 |
| Cash Conversion Cycle | 385.42 | 333.61 | 120.35 | 231.79 |